Generalized Myasthenia Gravis (gMG) is a condition where the immune system attacks the connection between nerves and muscles, causing muscle weakness. This study tests a new medicine called telitacicept to see if it helps people with gMG. Telitacicept works by stopping certain signals that cause the immune system to attack the body, which might help reduce symptoms.

This research is a Phase 3 study, meaning it's in the later stages of testing. The study is randomized and double-blind, so neither the doctors nor the patients know who is actually getting telitacicept or a placebo, which is a fake treatment. After this phase, everyone can choose to continue in an open-label extension where they know they’re receiving telitacicept.

• The study is for adults 18 and older with specific symptoms and test results for gMG.
• Participants must not have other autoimmune diseases or certain health conditions.
• Key exclusions include recent cancer, severe heart disease, or recent thymus surgery.